In detail, one patient with adenocarcinoma harboring a missense point mutation in IDH1 (R132C) received ivosidenib as a third-line treatment, resulting in a progression-free survival (PFS) of 3.4 months. This evidence concerns the gene IDH1 and adenocarcinoma.